巨大卵巢无性细胞瘤双侧发病一例
A Case of Bilateral Massive Ovarian Dysgerminoma
DOI: 10.12677/acm.2026.161040, PDF,   
作者: 蔡 颖:吉首大学医学院,湖南 吉首;邹普润:吉首大学第一附属医院(湘西自治州人民医院)妇二科,湖南 吉首;林 彤*:吉首大学医学院,湖南 吉首;吉首大学第一附属医院(湘西自治州人民医院)妇二科,湖南 吉首
关键词: 无性细胞瘤巨大卵巢肿瘤生育力保护辅助治疗Dysgerminoma Massive Ovarian Tumor Fertility Preservation Adjuvant Therapy
摘要: 无性细胞瘤是一种和精原细胞同源的卵巢恶性生殖细胞肿瘤(MOGCT),通常发病年龄较年轻,本文通过阐述巨大肿块手术方式决策及术后辅助化疗的治疗方案的选择,对于年轻女性患者的生育力保护及延长患者生存期治疗方案提供参考依据。报告1例17岁青春期女性卵巢无性细胞瘤病例,患者因左腹持续性疼痛就诊于吉首大学第一附属医院妇科,腹部体查扪及肿块上缘达剑突、两侧达腋中线,质中,边界尚清,活动度可,CA125、β-HCG明显升高,CA199轻度升高,剖腹探查术中冰冻病例考虑双侧冰冰均卵巢无性细胞瘤,行左侧附件切除 + 右侧卵巢囊肿剥除术,术中切除左侧附件重量4.3 kg,术后EP方案依托泊苷(etoposide)、顺铂(cisplatin)方案化疗同时给予亮丙瑞林保护卵巢功能治疗。现已随访17个月,目前患儿生存状况良好,月经规律,未发现肿瘤复发或转移。
Abstract: Dysgerminoma is a malignant ovarian germcell tumor (MOGCT) that originates from primordial germ cells and typically occurs in young patients. This article discusses the decision-making process for surgical management of a massive tumor and the selection of postoperative adjuvant chemotherapy regimens, providing reference for fertility preservation and extending survival in young female patients. We report a case of a 17-year-old adolescent with ovarian dysgerminoma who presented with persistent left-abdominal pain and was admitted to the Gynecology Department of the First Affiliated Hospital of Jishou University. Physical examination revealed a palpable mass extending superiorly to the xiphoid process and laterally to the mid-axillary lines; the mass was of medium consistency, with relatively clear borders and good mobility. Serum markers showed markedly elevated CA-125 and β-hCG, with mildly increased CA19-9. Intra-operative frozen section suggested bilateral ovarian dysgerminoma. The patient underwent left salpingo-oophorectomy combined with right ovarian cystectomy; the left adnexal specimen weighed 4.3 kg. Postoperatively, she received EP chemotherapy (etoposide +  cisplatin) together with GnRH-agonist (leuprolide) for ovarian function protection. After 17 months of follow-up, the patient remains in good condition, with regular menstruation and no evidence of tumor recurrence or metastasis.
文章引用:蔡颖, 邹普润, 林彤. 巨大卵巢无性细胞瘤双侧发病一例[J]. 临床医学进展, 2026, 16(1): 267-273. https://doi.org/10.12677/acm.2026.161040

参考文献

[1] Scott, A.R., Stoltzfus, K.C., Tchelebi, L.T., Trifiletti, D.M., Lehrer, E.J., Rao, P., et al. (2020) Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015. JAMA Network Open, 3, e2027738. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[3] 杨洁, 杨佳欣, 王瑾晖, 等. 卵巢恶性生殖细胞肿瘤临床诊治中国专家共识[J]. 现代妇产科进展, 2024, 33(8): 561-568.
[4] Warnnissorn, M., Watkins, J.C. and Young, R.H. (2021) Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems. American Journal of Surgical Pathology, 45, 1009-1027. [Google Scholar] [CrossRef] [PubMed]
[5] 杨祝萍, 许程洁. 无性细胞瘤突发破裂1例围术期护理[J]. 中国乡村医药, 2019, 26(11): 75-76.
[6] 李飞飞, 王鑫, 韩长年. 卵巢无性细胞瘤28例的磁共振成像表现与病理特征回顾分析[J]. 山西医药杂志, 2021, 50(8): 1257-1259.
[7] 韩晓明, 李乐. 卵巢无性细胞瘤1例及其CT特征[J]. 中国CT和MRI杂志, 2023, 21(5): 183-184.
[8] 齐冬雪, 张春芳, 张昶, 等. SALL4、CD30、D2-40和glypican-3在卵巢生殖细胞肿瘤中的表达及应用[J]. 诊断病理学杂志, 2017, 24(5): 358-362.
[9] 乔杰. 加强生育力保护切实提高出生人口素质[J]. 人口与健康, 2025(1): 34-37.
[10] 孙丹, 范江涛, 张师前, 等. 卵巢恶性肿瘤保留生育功能的中国专家共识(2022年版) [J]. 中国实用妇科与产科杂志, 2022, 38(7): 705-713.
[11] National Comprehensive Cancer Network (2024) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN Clinical Practice Guidelines in Oncology, 2024, Version 1.
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)卵巢癌诊疗指南2023 [M]. 北京: 人民卫生出版社, 2023.
[13] 中华医学会妇科肿瘤学分会, 中国医师协会妇产科医师分会妇科肿瘤学组. 卵巢恶性生殖细胞肿瘤临床诊治中国专家共识(2024 版) [EB/OL]. 2024.
https://www.obgy.cn/index/brand/details/id/11306.html, 2024-10-28.
[14] Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., et al. (2018) Ovarian Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284-296. [Google Scholar] [CrossRef] [PubMed]
[15] 卢淮武, 徐冬冬, 赵喜博, 等. 《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2024, 40(2): 187-197.
[16] 王珊. 儿童颅外生殖细胞肿瘤诊疗专家共识(CCCG-GCTs-2021) [J]. 中国小儿血液与肿瘤杂志, 2024, 29(1): 1-9.
[17] NCCN (2024) Clinical Practice Guidelines in Oncology-Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 1.
[18] 孙丹, 范江涛, 张师前, 等. 卵巢恶性肿瘤保留生育功能的中国专家共识(2022年版) [J]. 中国实用妇科与产科杂志, 2022, 38(7): 705-713.
[19] Shi, Z.Y., et al. (2025) Bola-Amphiphilic Dendrimer Empowers Imatinib to Target Metastatic Ovarian Cancer Stem Cells via β-Catenin-HRP2 Signaling Axis. CS Applied Materials & Interfaces, 17, 2884-2898.
[20] Gaffan, J., Holden, L., Newlands, E.S., Short, D., Fuller, S., Begent, R.H.J., et al. (2003) Infertility Rates Following POMB/ACE Chemotherapy for Male and Female Germ Cell Tumours—A Retrospective Long-Term Follow-Up Study. British Journal of Cancer, 89, 1849-1854. [Google Scholar] [CrossRef] [PubMed]
[21] Markowska, A., Antoszczak, M., Markowska, J. and Huczyński, A. (2024) Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms. Cancers, 16, Article No. 2288. [Google Scholar] [CrossRef] [PubMed]
[22] 李婧婧, 热孜宛古丽·艾斯凯尔, 李丹丹, 等. 不同治疗方案对卵巢恶性生殖细胞肿瘤患者生育能力影响的研究进展[J]. 吉林大学学报(医学版), 2023, 49(3): 816-822.
[23] Bedoschi, G., Navarro, P.A. and Oktay, K. (2016) Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact. Future Oncology, 12, 2333-2344. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, S., Liu, Q., Chang, M., Pan, Y., Yahaya, B.H., Liu, Y., et al. (2023) Chemotherapy Impairs Ovarian Function through Excessive ROS-Induced Ferroptosis. Cell Death & Disease, 14, Article No. 340. [Google Scholar] [CrossRef] [PubMed]
[25] Tamauchi, S., Kajiyama, H., Yoshihara, M., Ikeda, Y., Yoshikawa, N., Nishino, K., et al. (2018) Reproductive Outcomes of 105 Malignant Ovarian Germ Cell Tumor Survivors: A Multicenter Study. American Journal of Obstetrics and Gynecology, 219, 385.e1-385.e7. [Google Scholar] [CrossRef] [PubMed]
[26] de La Motte Rouge, T., Pautier, P., Rey, A., Duvillard, P., Kerbrat, P., Troalen, F., et al. (2011) Prognostic Factors in Women Treated for Ovarian Yolk Sac Tumour: A Retrospective Analysis of 84 Cases. European Journal of Cancer, 47, 175-182. [Google Scholar] [CrossRef] [PubMed]
[27] Capito, C., Arnaud, A., Hameury, F., Fremond, B., Lardy, H., Leclair, M.D., et al. (2011) Dysgerminoma and Gonadal Dysgenesis: The Need for a New Diagnosis Tree for Suspected Ovarian Tumours. Journal of Pediatric Urology, 7, 367-372. [Google Scholar] [CrossRef] [PubMed]